secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2025-12-31T23:59:59+00:00
Accession:  0001193125-25-337646
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla enters $40M SPV deal to advance Oz-V Phase 3; retains 65% ownership
---------------------------------------------------------------------------

- Total $40M from Inversagen AI for 35% of SPV units; initial $5M closing by Jan 30, 2026.
- BioAtla retains 65% ownership of Oz-V across all solid tumor indications after transaction.
- Proceeds fund Phase 3 trial for Oz-V in 2L+ OPSCC; enrollment expected to begin early 2026.
- Related-party transaction: Chairman/CEO Dr. Jay Short and spouse are managers of Inversagen entities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000119312525337646/0001193125-25-337646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000119312525337646/d20340d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-337646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer